Bull Flag Stocks
NGNE is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
NEUROGENE INC (NGNE) Stock Price & Overview
NASDAQ:NGNE • US64135M1053
Current stock price
26.85 USD
+0.76 (+2.91%)
At close:
26.85 USD
0 (0%)
After Hours:
The current stock price of NGNE is 26.85 USD. Today NGNE is up by 2.91%. In the past month the price increased by 29.77%. In the past year, price increased by 58.22%.
NGNE Key Statistics
52-Week Range11.77 - 37.2659
Current NGNE stock price positioned within its 52-week range.
1-Month Range19.1308 - 29.05
Current NGNE stock price positioned within its 1-month range.
- Market Cap
- 418.055M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.29
- Dividend Yield
- N/A
NGNE Stock Performance
Today
+2.91%
1 Week
-0.67%
1 Month
+29.77%
3 Months
+52.04%
Longer-term
6 Months -21.63%
1 Year +58.22%
2 Years -28.59%
3 Years N/A
5 Years N/A
10 Years N/A
NGNE Stock Chart
NGNE Stock Screens
NGNE currently appears in the following ChartMill screener lists.
NGNE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NGNE. When comparing the yearly performance of all stocks, NGNE is one of the better performing stocks in the market, outperforming 90.66% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NGNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NGNE. The financial health of NGNE is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NGNE Earnings
Next Earnings DateMay 8, 2026
Last Earnings DateMar 24, 2026
PeriodQ4 / 2025
EPS Reported-$1.17
Revenue Reported
EPS Surprise 3.49%
Revenue Surprise %
NGNE Forecast & Estimates
14 analysts have analysed NGNE and the average price target is 79.22 USD. This implies a price increase of 195.05% is expected in the next year compared to the current price of 26.85.
Analysts
Analysts85.71
Price Target79.22 (195.05%)
EPS Next Y-22.06%
Revenue Next YearN/A
NGNE Index Membership
NGNE is currently included in the following stock indexes tracked on ChartMill.
NGNE Financial Highlights
Over the last trailing twelve months NGNE reported a non-GAAP Earnings per Share(EPS) of -4.29. The EPS decreased by -0.47% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-90.35M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.31% | ||
| ROE | -34.11% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-18.18%
Sales Q2Q%N/A
EPS 1Y (TTM)-0.47%
Revenue 1Y (TTM)-100%
NGNE Ownership
Ownership
Inst Owners108.88%
Shares15.57M
Float14.21M
Ins Owners8.75%
Short Float %28.23%
Short Ratio21.5
NGNE Industry Overview
NGNE operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
NGNE Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NGNE
Company Profile
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
Company Info
IPO: 2014-03-07
NEUROGENE INC
535 W 24Th Street, 5Th Floor
New York City NEW YORK US
Employees: 107
Phone: 13026587581
NEUROGENE INC / NGNE FAQ
What does NGNE do?
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
What is the current price of NGNE stock?
The current stock price of NGNE is 26.85 USD. The price increased by 2.91% in the last trading session.
Does NGNE stock pay dividends?
NGNE does not pay a dividend.
What is the ChartMill rating of NEUROGENE INC stock?
NGNE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists NGNE stock?
NGNE stock is listed on the Nasdaq exchange.
How many employees does NEUROGENE INC have?
NEUROGENE INC (NGNE) currently has 107 employees.
What is the Short Interest ratio of NEUROGENE INC (NGNE) stock?
The outstanding short interest for NEUROGENE INC (NGNE) is 28.23% of its float.